CheckMate 649 3-Year Follow-up: Nivolumab Plus Chemotherapy for Gastric and Esophageal Cancers

CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC

Checkmate 649 | Out now on Plenary Session Podcast feed

Overview of gastroesophageal cancer

【JCF2023】胃がん

CheckMate 9ER: cabo-nivo superior to sunitinib in extended follow-up results

CheckMate 459: Nivolumab plus chemotherapy for GC / GEJC / EAC

Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers

2021 International Gastric Cancer Educational Symposium - Session 3

Advanced Gastroesophageal Cancers: Maximizing the Benefits of Novel Immunotherapy Approaches

Immunotherapy | Oesophageal Cancer | Gastric Cancer | Advanced Cancer Treatment

CheckMate 459: updates on nivolumab monotherapy for HCC

8 in 8: Update on Immunotherapy for Resectable Lung Cancer

Updates from CheckMate 040 in Asian HCC patients

Clinical Trials Updates for Gastric Cancer Patients Webinar

Navigating Multidisciplinary Care With Immunotherapy in Esophageal/GEJ Cancer

Oncology 2022 Looking Ahead

Management of Esophageal/GEJ Cancers: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy

HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy